------------------------------

                                                        OMB APPROVAL

                                                   OMB Number: 3235-0145
                                                   Expires: February 28, 2009
                                                    Estimated average burden
                                                    hours per response  10.4
                                                 ------------------------------

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  SCHEDULE 13G

                    UNDER THE SECURITIES EXCHANGE ACT OF 1934

                               (AMENDMENT NO. 1)*



                           DUSA PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
                                (Name of Issuer)


                                  COMMON STOCK
--------------------------------------------------------------------------------
                         (Title of Class of Securities)



                                    266898105
--------------------------------------------------------------------------------
                                 (CUSIP Number)


                                DECEMBER 31, 2007
--------------------------------------------------------------------------------
             (Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

|_|  Rule 13d-1(b)

|X|  Rule 13d-1(c)

|_|  Rule 13d-1(d)


*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).



PERSONS WHO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE
NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL
NUMBER.


                                       1


------------------------                                 -----------------------
 CUSIP No.  266898105                 13G/A               Page 2 of 9 Pages
------------------------                                 -----------------------



    1.   NAMES OF REPORTING PERSONS

         Great Point Partners, LLC

         I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

         37-1475292

    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         (a)   |_|

         (b)   |_|

--------------------------------------------------------------------------------

    3.   SEC USE ONLY


--------------------------------------------------------------------------------

    4.   CITIZENSHIP OR PLACE OF ORGANIZATION

         USA

 NUMBER OF SHARES     5.    SOLE VOTING POWER
                                                         0
   BENEFICIALLY       6.    SHARED VOTING POWER
                                                     1,150,000
  OWNED BY EACH       7.    SOLE DISPOSITIVE POWER
                                                         0
 REPORTING PERSON     8.    SHARED DISPOSITIVE POWER
                                                     1,150,000
       WITH

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                     1,150,000

   10.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
         SHARES (See Instructions)                                           |_|


   11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

                     4.78%

   12.   TYPE OF REPORTING PERSON (See Instructions)

                     OO



------------------------                                 -----------------------
 CUSIP No.  266898105                 13G/A               Page 3 of 9 Pages
------------------------                                 -----------------------



    1.   NAMES OF REPORTING PERSONS

         Dr. Jeffrey R. Jay, M.D.

         I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):



    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         (a)   |_|

         (b)   |_|

--------------------------------------------------------------------------------

    3.   SEC USE ONLY


--------------------------------------------------------------------------------

    4.   CITIZENSHIP OR PLACE OF ORGANIZATION

         USA

 NUMBER OF SHARES     5.    SOLE VOTING POWER
                                                         0
   BENEFICIALLY       6.    SHARED VOTING POWER
                                                     1,150,000
  OWNED BY EACH       7.    SOLE DISPOSITIVE POWER
                                                         0
 REPORTING PERSON     8.    SHARED DISPOSITIVE POWER
                                                     1,150,000
       WITH

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                     1,150,000

   10.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
         SHARES (See Instructions)                                           |_|


   11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

                     4.78%

   12.   TYPE OF REPORTING PERSON (See Instructions)

                     IN



------------------------                                 -----------------------
 CUSIP No.  266898105                 13G/A               Page 4 of 9 Pages
------------------------                                 -----------------------



    1.   NAMES OF REPORTING PERSONS

         Mr. David Kroin

         I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):



    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         (a)   |_|

         (b)   |_|

--------------------------------------------------------------------------------

    3.   SEC USE ONLY


--------------------------------------------------------------------------------

    4.   CITIZENSHIP OR PLACE OF ORGANIZATION

         USA

 NUMBER OF SHARES     5.    SOLE VOTING POWER
                                                         0
   BENEFICIALLY       6.    SHARED VOTING POWER
                                                     1,150,000
  OWNED BY EACH       7.    SOLE DISPOSITIVE POWER
                                                         0
 REPORTING PERSON     8.    SHARED DISPOSITIVE POWER
                                                     1,150,000
       WITH

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                     1,150,000

   10.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
         SHARES (See Instructions)                                           |_|


   11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

                     4.78%

   12.   TYPE OF REPORTING PERSON (See Instructions)

                     IN




------------------------                                 -----------------------
 CUSIP No.  266898105                 13G/A               Page 5 of 9 Pages
------------------------                                 -----------------------



    ITEM 1.

                 (a)      Name of Issuer

                          DUSA Pharmaceuticals, Inc.

                 (b)      Address of Issuer's Principal Executive Offices

                          25 Upton Drive, Wilmington, MA  01887

    ITEM 2.

                 (a)      Name of Person Filing

                                    Great Point Partners, LLC
                                    Dr. Jeffrey R. Jay, M.D.
                                    Mr. David Kroin

                 The Reporting Persons have entered into a Joint Filing
                 Agreement, dated February 14, 2008, a copy of which is filed
                 with this Schedule 13G/A as Exhibit A, pursuant to which the
                 Reporting Persons have agreed to file this statement jointly in
                 accordance with the provisions of Rule 13d-1(k)(1) under the
                 Act.

                 (b)      Address of Principal Business Office, or if none,
                          Residence

                          The address of the principal business office of each
                          of the Reporting Persons is

                               165 Mason Street, 3rd Floor
                               Greenwich, CT 06830

                 (c)      Citizenship

                 Great Point Partners, LLC is a limited liability company
                 organized under the laws of the State of Delaware. Dr. Jeffrey
                 R. Jay, M.D. is a citizen of the United States. Mr. David Kroin
                 is a citizen of the United States.

                 (d)      Title of Class of Securities

                          Common Stock

                 (e)      CUSIP Number

                          266898105

    ITEM 3.      IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13D-1(b) OR
                 240.13D.2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

                          Not Applicable.

                 (a)   |_|   Broker or dealer registered under Section 15 of the
                             Act (15 U.S.C. 78o)

                 (b)   |_|   Bank as defined in Section 3(a)(6) of the Act
                             (15 U.S.C. 78c).

                 (c)   |_|   Insurance company as defined in Section 3(a)(19)
                             of the Act (15. U.S.C. 78c).

                 (d)   |_|   Investment Company registered under Section 8 of
                             the Investment Company Act of 1940
                             (15 U.S.C. 80a-8).

                 (e)   |_|   An investment adviser in accordance with
                             ss.240.13d-1(b)(1)(ii)(E).


------------------------                                 -----------------------
 CUSIP No.  266898105                 13G/A               Page 6 of 9 Pages
------------------------                                 -----------------------



                 (f)   |_|   An employee benefit plan or endowment fund in
                             accordance with ss.240.13d-1(b)(1)(ii)(F).

                 (g)   |_|   A parent holding company or control person in
                             accordance with ss.240.13d-1(b)(1)(ii)(G).

                 (h)   |_|   A savings associations as defined in Section
                             3(b) of the Federal Deposit Insurance Act (12
                             U.S.C. 1813).

                 (i)   |_|   A church plan that is excluded from the
                             definition of an investment company under
                             Section 3(c)(14) of the Investment Company Act
                             of 1940 (15 U.S.C. 80a-3).

                 (j)   |_|   Group, in accordance with
                             ss.240.13d-1(b)(1)(ii)(J).

    ITEM 4.      OWNERSHIP

                 Great Point Partners, LLC ("Great Point") is the investment
                 manager of Biomedical Value Fund, L.P. ("BVF"), and by virtue
                 of such status may be deemed to be the beneficial owner of the
                 621,001 shares of Common Stock of the Issuer owned by BVF (the
                 "BVF Shares"). Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as
                 senior managing member of Great Point, and Mr. David Kroin
                 ("Mr. Kroin"), as special managing member of Great Point, has
                 voting and investment power with respect to the BVF Shares, and
                 therefore may be deemed to be the beneficial owner of the BVF
                 Shares.

                 Great Point is the investment manager of Biomedical Offshore
                 Value Fund, Ltd. ("BOVF"), and by virtue of such status may be
                 deemed to be the beneficial owner of the 528,999 shares of
                 Common Stock of the Issuer owned by BOVF (the "BOVF Shares").
                 Each of Dr. Jay, as senior managing member of Great Point, and
                 Mr. Kroin, as special managing member of Great Point, has
                 voting and investment power with respect to the BOVF Shares,
                 and therefore may be deemed to be the beneficial owner of the
                 BOVF Shares.

                 Great Point, Dr. Jay and Mr. Kroin disclaim beneficial
                 ownership of the BVF Shares and the BOVF Shares, except to the
                 extent of their respective pecuniary interest.


                 Provide the following information regarding the aggregate
                 number and percentage of the class of securities of the issuer
                 identified in Item 1.

                 1.       GREAT POINT PARTNERS, LLC

                 (a)      Amount beneficially owned: 1,150,000

                 (b)      Percent of class: 4.78%

                 (c)      Number of shares as to which the person has:

                          (i)   Sole power to vote or to direct the vote:  - 0 -

                          (ii)  Shared power to vote or to direct the vote:
                                1,150,000

                          (iii) Sole power to dispose or to direct the
                                disposition of:   - 0 -.

                          (iv)  Shared power to dispose or to direct the
                                disposition of: 1,150,000

                 2.       DR. JEFFREY R. JAY, M.D.

                 (a)      Amount beneficially owned: 1,150,000

                 (b)      Percent of class: 4.78%


------------------------                                 -----------------------
 CUSIP No.  266898105                 13G/A               Page 7 of 9 Pages
------------------------                                 -----------------------



                 (c)      Number of shares as to which the person has:

                          (i)   Sole power to vote or to direct the vote: 0.

                          (ii)  Shared power to vote or to direct the vote:
                                1,150,000

                          (iii) Sole power to dispose or to direct the
                                disposition of: 0.

                          (iv)  Shared power to dispose or to direct the
                                disposition of: 1,150,000

                 3.       MR. DAVID KROIN

                 (a)      Amount beneficially owned: 1,150,000

                 (b)      Percent of class: 4.78%

                 (c)      Number of shares as to which the person has:

                          (i)   Sole power to vote or to direct the vote: 0.

                          (ii)  Shared power to vote or to direct the vote:
                                1,150,000

                          (iii) Sole power to dispose or to direct the
                                disposition of: 0.

                          (iv)  Shared power to dispose or to direct the
                                disposition of: 1,150,000


    ITEM 5.      OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

                 If this statement is being filed to report the fact that as of
                 the date hereof each of the Reporting Persons has ceased to be
                 the beneficial owner of more than five percent of the class of
                 securities, check the following [X].

    ITEM 6.      OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER
                 PERSON:

                 See Item 4.

                 ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY
                 WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT
                 HOLDING COMPANY

                 Not Applicable.

    ITEM 8.      IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

                 Not Applicable.

    ITEM 9.      NOTICE OF DISSOLUTION OF GROUP

                 Not Applicable.

    ITEM 10.     CERTIFICATION

    By signing below I certify that, to the best of my knowledge and belief, the
    securities referred to above were not acquired and are not held for the
    purpose of or with the effect of changing or influencing the control of the
    issuer of the securities and were not acquired and are not held in
    connection with or as participant in any transaction having that purpose or
    effect.


------------------------                                 -----------------------
 CUSIP No.  266898105                 13G/A               Page 8 of 9 Pages
------------------------                                 -----------------------



                                    SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.

Date:  February 14, 2008

                            GREAT POINT PARTNERS, LLC

                            By:  /s/ Dr. Jeffrey R. Jay, M.D.
                                 -------------------------------------------
                                 Dr. Jeffrey R. Jay, M.D.,
                                  as senior managing member

                            /s/ Dr. Jeffrey R. Jay, M.D.
                            ------------------------------------------------
                            DR. JEFFREY R. JAY, M.D.

                            /s/ Mr. David Kroin
                            ------------------------------------------------
                            MR. DAVID KROIN




                                                                       EXHIBIT A


             AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G/A


The undersigned hereby agree as follows:

         (i)      Each of them is individually eligible to use the Schedule
13G/A to which this Exhibit is attached, and such Schedule 13G/A is filed on
behalf of each of them; and

         (ii)     Each of them is responsible for the timely filing of such
Schedule 13G/A and any amendments thereto, and for the completeness and accuracy
of the information concerning such person contained therein; but none of them is
responsible for the completeness or accuracy of the information concerning the
other persons making the filing, unless such person knows or has reason to
believe that such information is inaccurate.

Date:  February 14, 2008

                             GREAT POINT PARTNERS, LLC

                            By:  /s/ Dr. Jeffrey R. Jay, M.D.
                                 -------------------------------------------
                                 Dr. Jeffrey R. Jay, M.D.,
                                  as senior managing member

                            /s/ Dr. Jeffrey R. Jay, M.D.
                            ------------------------------------------------
                            DR. JEFFREY R. JAY, M.D.

                            /s/ Mr. David Kroin
                            ------------------------------------------------
                            MR. DAVID KROIN